Literature DB >> 15001461

Contribution of eotaxin-1 to eosinophil chemotactic activity of moderate and severe asthmatic sputum.

Gordon Dent1, Chrystalleni Hadjicharalambous, Takahiro Yoshikawa, Rachel L C Handy, John Powell, Ian K Anderson, Renaud Louis, Donna E Davies, Ratko Djukanovic.   

Abstract

The CC chemokine eotaxin-1 (CCL11) is chemotactic for eosinophils, basophils, and type 2 helper T cells and may play a role in allergic inflammation. We investigated its contribution as an eosinophil chemoattractant in asthmatic airway secretions (sampled as induced sputum), which possess chemotactic activity for eosinophils and T cells. Sputum samples collected from healthy subjects and subjects with mild, stable-moderate, unstable-moderate, and severe asthma were processed with phosphate-buffered saline and assayed for eotaxin by ELISA and for eosinophil chemotactic activity by fluorescence-based chemotaxis assay. The contribution of eotaxin to chemotactic activity was studied by using a high-affinity neutralizing human anti-eotaxin antibody, CAT-213. Sputum eotaxin concentration was significantly raised in moderate and severe asthma (p < 0.05 versus healthy control subjects) but not in mild asthma. Chemotactic activity was significantly increased in all asthmatic groups relative to healthy subjects (p < 0.05) and was significantly inhibited by CAT-213 (100 nM) in subjects with moderate and severe asthma, with median inhibition of 52% (p < 0.05), 78% (p < 0.0001), and 86% (p < 0.0001), respectively, in samples representing stable-moderate, unstable-moderate, and severe asthma. Eotaxin contributed to the eosinophil chemotactic activity of sputum from subjects with more severe forms of asthma but not mild asthma, suggesting that its contribution is more important in more severe disease. This activity is inhibited significantly by CAT-213.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15001461     DOI: 10.1164/rccm.200306-855OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  13 in total

1.  The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications.

Authors:  Tomer Adar; Shimon Shteingart; Ami Ben-Ya'acov; Ariella Bar-Gill Shitrit; Dan M Livovsky; Shimrit Shmorak; Mahmud Mahamid; Bernardo Melamud; Fiona Vernea; Eran Goldin
Journal:  Dig Dis Sci       Date:  2016-02-13       Impact factor: 3.199

2.  Effects of 60-day bed rest with and without exercise on cellular and humoral immunological parameters.

Authors:  Paula Hoff; Daniel L Belavý; Dörte Huscher; Annemarie Lang; Martin Hahne; Anne-Kathrin Kuhlmey; Patrick Maschmeyer; Gabriele Armbrecht; Rudolf Fitzner; Frank H Perschel; Timo Gaber; Gerd-Rüdiger Burmester; Rainer H Straub; Dieter Felsenberg; Frank Buttgereit
Journal:  Cell Mol Immunol       Date:  2014-11-10       Impact factor: 11.530

Review 3.  Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.

Authors:  Michelle Fox Huffaker; Wanda Phipatanakul
Journal:  Immunol Allergy Clin North Am       Date:  2014-11-21       Impact factor: 3.479

4.  Eotaxin-1 in exhaled breath condensate of stable and unstable asthma patients.

Authors:  Ziemowit Zietkowski; Maria M Tomasiak-Lozowska; Roman Skiepko; Elzbieta Zietkowska; Anna Bodzenta-Lukaszyk
Journal:  Respir Res       Date:  2010-08-12

Review 5.  Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.

Authors:  Michael Camilleri
Journal:  J Clin Invest       Date:  2013-10-01       Impact factor: 14.808

6.  Cytokines in chronic respiratory diseases.

Authors:  Sergei P Atamas; Svetlana P Chapoval; Achsah D Keegan
Journal:  F1000 Biol Rep       Date:  2013-02-01

7.  Regulation of Eosinophil and Group 2 Innate Lymphoid Cell Trafficking in Asthma.

Authors:  Marie-Chantal Larose; Anne-Sophie Archambault; Véronique Provost; Michel Laviolette; Nicolas Flamand
Journal:  Front Med (Lausanne)       Date:  2017-08-11

8.  A novel microbe-based treatment that attenuates the inflammatory profile in a mouse model of allergic airway disease.

Authors:  Mark Bazett; Agnieszka Biala; Ryan D Huff; Momir Bosiljcic; Hal Gunn; Shirin Kalyan; Jeremy A Hirota
Journal:  Sci Rep       Date:  2016-10-13       Impact factor: 4.379

9.  Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma.

Authors:  Bart Hilvering; Timothy S C Hinks; Linda Stöger; Emanuele Marchi; Maryam Salimi; Rahul Shrimanker; Wei Liu; Wentao Chen; Jian Luo; Simei Go; Timothy Powell; Jennifer Cane; Samantha Thulborn; Ayako Kurioka; Tianqi Leng; Jamie Matthews; Clare Connolly; Catherine Borg; Mona Bafadhel; Christian B Willberg; Adaikalavan Ramasamy; Ratko Djukanović; Graham Ogg; Ian D Pavord; Paul Klenerman; Luzheng Xue
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

10.  The loss of Hoxa5 function promotes Notch-dependent goblet cell metaplasia in lung airways.

Authors:  Olivier Boucherat; Jamila Chakir; Lucie Jeannotte
Journal:  Biol Open       Date:  2012-05-29       Impact factor: 2.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.